Psychol Health 2004, 19: 749–765 CrossRef 10 Schlich-Bakker KJ,

Psychol Health 2004, 19: 749–765.CrossRef 10. Schlich-Bakker KJ, ten Kroode HFJ, Ausems MGEM: A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006, 60: 13–20.CrossRef 11. Kelly K, Leventhal H, Marvin M, Toppmeyer D, Much J, Dermody J, Baran J, Schwalb M: Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.

Genet Test 2004, 8: 139–47.PubMed 12. Kelly KM, Senter L, Leventhal H, Ozakinci G, Porter K: Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations. Patient Educ Couns 2008, 70: 135–142.CrossRefPubMed 13. D’Agincourt-Canning L: The effect of experimental knowledge on construction of risk perception in hereditary breast/ovarian cancer. J Genet Couns 2005, 14: 55–69.CrossRefPubMed 14. Katapodi MC, Lee KA, Facione NC, Dodd MJ: buy BKM120 Predictors of perceived breast cancer risk and relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med 2004, 39: 388–402.CrossRef 15. Daly MB, Lerman C, Ross E, Schwartz MD, Sands CB, Masny ATM signaling pathway A: Gail Model breast cancer risk components are poor predictors of risk perception and screening behaviour. Breast Cancer Res Treat 1996, 41: 59–70.CrossRefPubMed 16.

Walter FM, Emery J, Braithwaite D, Marteau TM: Lay understanding of familial risk of common chronic disease: A systematic review and synthesis of qualitative research. Ann Fam Med 2004, 2: 583–594.CrossRefPubMed 17. Quillin JM, McClish DK, Jones RM, Burruss K, Bodurtha JN: Spiritual coping, family history and perceived risk for breast cancer-can we make sense of it? J Genet Couns 2006, 15: 449–460.CrossRefPubMed 18. Gil F, Mendez

I, Sirgo A, Llort G, Blanco I, Cortes-Funes L: Perception of breast cancer risk and surveillance behaviours of women with family history of breast cancer: a brief report on a Spanish cohort. Psychooncology 2003, 12: 821–827.CrossRefPubMed Chlormezanone 19. Caruso A, Vigna C, Maggi G, Sega FM, Cognetti F, Savarese A: The withdrawal from oncogenetic counseling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample. J Exp Clin Cancer Res 2008, 27: 75–82.CrossRefPubMed 20. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G: BRCAPRO validation, sensitivity of genetic testing of BRCA1/2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002, 20: 2701–2712.CrossRefPubMed 21. Parmigiani G, Berry DA, Aguilar O: Modelling risk of breast cancer and decisions about genetic testing. Am J Hum Genet 1998, 62: 145–148.CrossRefPubMed 22.

Related posts:

  1. Pazopanib in BRCA1/2 genes have been detected in reliable tumors
  2. We have screened for BRCA1 and BRCA2 mutations 110 women diagnose
  3. Comparison of PR and HER2 status involving ER BRCA1 breast cancer
  4. Cancer Genet Cytogenet 2003, 140: 145–152 CrossRefPubMed 10 Cher
  5. CrossRef 17 Quaglino P, Ribero S, Osella-Abate S, Macrì L, Grass
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>